Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OccuLogix, a company focused on the treatment of age-related eye disease, has completed its acquisition of Solx.
Subscribe to our email newsletter
Solx, a privately-held company developing new treatments for glaucoma, has developed its DeepLight system, which can be used to provide patients with multiple options for intraocular pressure reduction. The treatment includes the DeepLight 790 Titanium Sapphire Laser and the DeepLight Gold-Micro Shunt (GMS). The Deeplight 790 has been shown to offer a more efficient treatment than other lasers currently in use and the therapeutic has been shown to provide deeper tissue penetration.
The DeepLight 790 and the DeepLight GMS have received international CE approval and are currently the subjects of two randomized, multi-center studies being conducted in the US.
OccuLogix acquired Solx by way of a merger of Solx and a wholly owned subsidiary of OccuLogix, with Solx surviving the merger and becoming a wholly owned subsidiary of OccuLogix. Doug Adams, Solx’ president and CEO, has joined OccuLogix as president of the new subsidiary.
“Like our Rheo System for the treatment of dry AMD, the DeepLight System has the potential to significantly improve the lives of patients while also changing the paradigm by which physicians view and treat age-related eye diseases,” commented Elias Vamvakas, OccuLogix chairman and CEO.